A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Latest Information Update: 10 Nov 2021
At a glance
- Drugs INO 1001 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Inotek Pharmaceuticals
- 30 Nov 2006 Status change
- 09 Nov 2006 New trial record.